NL8303506A - Toeslagstof voor voedingsbodems voor het kweken van campylobacter jejuni. - Google Patents
Toeslagstof voor voedingsbodems voor het kweken van campylobacter jejuni. Download PDFInfo
- Publication number
- NL8303506A NL8303506A NL8303506A NL8303506A NL8303506A NL 8303506 A NL8303506 A NL 8303506A NL 8303506 A NL8303506 A NL 8303506A NL 8303506 A NL8303506 A NL 8303506A NL 8303506 A NL8303506 A NL 8303506A
- Authority
- NL
- Netherlands
- Prior art keywords
- cefoperazone
- rifampicin
- amphotericin
- additive
- mixture
- Prior art date
Links
- 241000589875 Campylobacter jejuni Species 0.000 title claims description 14
- 235000015097 nutrients Nutrition 0.000 title description 21
- 239000013589 supplement Substances 0.000 title description 9
- 239000000203 mixture Substances 0.000 claims description 40
- GCFBRXLSHGKWDP-XCGNWRKASA-N cefoperazone Chemical compound O=C1C(=O)N(CC)CCN1C(=O)N[C@H](C=1C=CC(O)=CC=1)C(=O)N[C@@H]1C(=O)N2C(C(O)=O)=C(CSC=3N(N=NN=3)C)CS[C@@H]21 GCFBRXLSHGKWDP-XCGNWRKASA-N 0.000 claims description 23
- 229960004682 cefoperazone Drugs 0.000 claims description 23
- 239000000654 additive Substances 0.000 claims description 22
- 230000000996 additive effect Effects 0.000 claims description 19
- 239000001963 growth medium Substances 0.000 claims description 19
- JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 claims description 18
- 229960001225 rifampicin Drugs 0.000 claims description 18
- 108010078777 Colistin Proteins 0.000 claims description 11
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 claims description 11
- 229960003346 colistin Drugs 0.000 claims description 11
- JORAUNFTUVJTNG-BSTBCYLQSA-N n-[(2s)-4-amino-1-[[(2s,3r)-1-[[(2s)-4-amino-1-oxo-1-[[(3s,6s,9s,12s,15r,18s,21s)-6,9,18-tris(2-aminoethyl)-3-[(1r)-1-hydroxyethyl]-12,15-bis(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-h Chemical compound CC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@H]([C@@H](C)O)CN[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O.CCC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@H]([C@@H](C)O)CN[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O JORAUNFTUVJTNG-BSTBCYLQSA-N 0.000 claims description 11
- XDJYMJULXQKGMM-UHFFFAOYSA-N polymyxin E1 Natural products CCC(C)CCCCC(=O)NC(CCN)C(=O)NC(C(C)O)C(=O)NC(CCN)C(=O)NC1CCNC(=O)C(C(C)O)NC(=O)C(CCN)NC(=O)C(CCN)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CCN)NC1=O XDJYMJULXQKGMM-UHFFFAOYSA-N 0.000 claims description 11
- KNIWPHSUTGNZST-UHFFFAOYSA-N polymyxin E2 Natural products CC(C)CCCCC(=O)NC(CCN)C(=O)NC(C(C)O)C(=O)NC(CCN)C(=O)NC1CCNC(=O)C(C(C)O)NC(=O)C(CCN)NC(=O)C(CCN)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CCN)NC1=O KNIWPHSUTGNZST-UHFFFAOYSA-N 0.000 claims description 11
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 claims description 9
- 241000589876 Campylobacter Species 0.000 claims description 9
- 229960003942 amphotericin b Drugs 0.000 claims description 9
- 230000000721 bacterilogical effect Effects 0.000 claims description 8
- 239000002671 adjuvant Substances 0.000 claims description 7
- 239000013543 active substance Substances 0.000 claims description 6
- 230000003377 anti-microbal effect Effects 0.000 claims description 4
- 230000000845 anti-microbial effect Effects 0.000 claims description 3
- 229930183010 Amphotericin Natural products 0.000 claims description 2
- QGGFZZLFKABGNL-UHFFFAOYSA-N Amphotericin A Natural products OC1C(N)C(O)C(C)OC1OC1C=CC=CC=CC=CCCC=CC=CC(C)C(O)C(C)C(C)OC(=O)CC(O)CC(O)CCC(O)C(O)CC(O)CC(O)(CC(O)C2C(O)=O)OC2C1 QGGFZZLFKABGNL-UHFFFAOYSA-N 0.000 claims description 2
- 229940009444 amphotericin Drugs 0.000 claims description 2
- 230000000844 anti-bacterial effect Effects 0.000 claims 2
- 238000002955 isolation Methods 0.000 description 8
- 239000002609 medium Substances 0.000 description 7
- 239000004599 antimicrobial Substances 0.000 description 5
- YPHMISFOHDHNIV-FSZOTQKASA-N cycloheximide Chemical compound C1[C@@H](C)C[C@H](C)C(=O)[C@@H]1[C@H](O)CC1CC(=O)NC(=O)C1 YPHMISFOHDHNIV-FSZOTQKASA-N 0.000 description 5
- 239000002689 soil Substances 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- 241001494479 Pecora Species 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000007382 columbia agar Substances 0.000 description 3
- 108010001478 Bacitracin Proteins 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- YJQPYGGHQPGBLI-UHFFFAOYSA-N Novobiocin Natural products O1C(C)(C)C(OC)C(OC(N)=O)C(O)C1OC1=CC=C(C(O)=C(NC(=O)C=2C=C(CC=C(C)C)C(O)=CC=2)C(=O)O2)C2=C1C YJQPYGGHQPGBLI-UHFFFAOYSA-N 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 229960003071 bacitracin Drugs 0.000 description 2
- 229930184125 bacitracin Natural products 0.000 description 2
- CLKOFPXJLQSYAH-ABRJDSQDSA-N bacitracin A Chemical compound C1SC([C@@H](N)[C@@H](C)CC)=N[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]1C(=O)N[C@H](CCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2N=CNC=2)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCCCC1 CLKOFPXJLQSYAH-ABRJDSQDSA-N 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- MLYYVTUWGNIJIB-BXKDBHETSA-N cefazolin Chemical compound S1C(C)=NN=C1SCC1=C(C(O)=O)N2C(=O)[C@@H](NC(=O)CN3N=NN=C3)[C@H]2SC1 MLYYVTUWGNIJIB-BXKDBHETSA-N 0.000 description 2
- 229960001139 cefazolin Drugs 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 229960002950 novobiocin Drugs 0.000 description 2
- YJQPYGGHQPGBLI-KGSXXDOSSA-N novobiocin Chemical compound O1C(C)(C)[C@H](OC)[C@@H](OC(N)=O)[C@@H](O)[C@@H]1OC1=CC=C(C(O)=C(NC(=O)C=2C=C(CC=C(C)C)C(O)=CC=2)C(=O)O2)C2=C1C YJQPYGGHQPGBLI-KGSXXDOSSA-N 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 208000005577 Gastroenteritis Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- IEDVJHCEMCRBQM-UHFFFAOYSA-N trimethoprim Chemical compound COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 IEDVJHCEMCRBQM-UHFFFAOYSA-N 0.000 description 1
- 229960001082 trimethoprim Drugs 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
- C12Q1/04—Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor
- C12Q1/045—Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
- C12Q1/18—Testing for antimicrobial activity of a material
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19823238819 DE3238819A1 (de) | 1982-10-20 | 1982-10-20 | Zusatz fuer naehrboeden zur zuechtung von campylobacter jejuni |
| DE3238819 | 1982-10-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NL8303506A true NL8303506A (nl) | 1984-05-16 |
Family
ID=6176152
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NL8303506A NL8303506A (nl) | 1982-10-20 | 1983-10-12 | Toeslagstof voor voedingsbodems voor het kweken van campylobacter jejuni. |
Country Status (7)
| Country | Link |
|---|---|
| JP (1) | JPH062048B2 (enExample) |
| BE (1) | BE897927A (enExample) |
| DE (1) | DE3238819A1 (enExample) |
| FR (1) | FR2534929B1 (enExample) |
| GB (1) | GB2129013B (enExample) |
| IT (1) | IT1164439B (enExample) |
| NL (1) | NL8303506A (enExample) |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2301211C3 (de) * | 1973-01-11 | 1978-06-22 | C.H. Boehringer Sohn, 6507 Ingelheim | Synthetisches Nährmedium für Mikroorganismen |
| US4229530A (en) * | 1978-08-29 | 1980-10-21 | Board Of Regents, University Of Texas System | Methods and media for rapid detection of pathogenic neisseria |
-
1982
- 1982-10-20 DE DE19823238819 patent/DE3238819A1/de active Granted
-
1983
- 1983-09-07 JP JP58165842A patent/JPH062048B2/ja not_active Expired - Lifetime
- 1983-09-20 IT IT22931/83A patent/IT1164439B/it active
- 1983-09-26 GB GB08325721A patent/GB2129013B/en not_active Expired
- 1983-10-05 BE BE6/47883A patent/BE897927A/fr not_active IP Right Cessation
- 1983-10-12 NL NL8303506A patent/NL8303506A/nl not_active Application Discontinuation
- 1983-10-19 FR FR8316656A patent/FR2534929B1/fr not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| IT1164439B (it) | 1987-04-08 |
| FR2534929B1 (fr) | 1985-11-22 |
| IT8322931A0 (it) | 1983-09-20 |
| BE897927A (fr) | 1984-01-30 |
| GB2129013B (en) | 1985-09-25 |
| FR2534929A1 (fr) | 1984-04-27 |
| DE3238819C2 (enExample) | 1990-04-12 |
| IT8322931A1 (it) | 1985-03-20 |
| DE3238819A1 (de) | 1984-04-26 |
| JPH062048B2 (ja) | 1994-01-12 |
| GB8325721D0 (en) | 1983-10-26 |
| JPS6037978A (ja) | 1985-02-27 |
| GB2129013A (en) | 1984-05-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Geudens et al. | Cyclic lipodepsipeptides from Pseudomonas spp.–biological swiss-army knives | |
| Thenmozhi et al. | Antibiofilm activity of coral-associated bacteria against different clinical M serotypes of Streptococcus pyogenes | |
| Van Arnam et al. | Defense contracts: molecular protection in insect-microbe symbioses | |
| US20200131096A1 (en) | Biofertilizer Composition and Method of Manufacture | |
| Wallin-Carlquist et al. | Prolonged expression and production of Staphylococcus aureus enterotoxin A in processed pork meat | |
| Itzek et al. | Hydrogen peroxide-dependent DNA release and transfer of antibiotic resistance genes in Streptococcus gordonii | |
| Chhetri et al. | A potential protective culture; halophilic Bacillus isolates with bacteriocin encoding gene against Staphylococcus aureus in salt added foods | |
| Chaabouni et al. | Secondary metabolites of Bacillus: potentials in biotechnology | |
| Liu et al. | High in vitro antimicrobial activity of β-peptoid–peptide hybrid oligomers against planktonic and biofilm cultures of Staphylococcus epidermidis | |
| Motta et al. | Characterization of a broad range antibacterial substance from a new Bacillus species isolated from Amazon basin | |
| Pathma et al. | Secondary metabolite production by bacterial antagonists | |
| EP1071416A1 (en) | Inhibition of gram positive bacteria | |
| Torracchi C et al. | Fighting plant pathogens with cold-active microorganisms: biopesticide development and agriculture intensification in cold climates | |
| Lo Giudice et al. | Antimicrobial potential of cold-adapted bacteria and fungi from polar regions | |
| da Silva et al. | Using antagonistic soil bacteria and their cell‐free filtrates to control the black rot pathogen Xanthomonas campestris pv. campestris | |
| Lihan et al. | Antimicrobial producing microbes isolated from soil samples collected from Nanga Merit Forest in Sarawak, Malaysian Borneo | |
| Dutta et al. | High‐throughput analysis of genes involved in biocontrol performance of Pseudomonas fluorescens NBC275 against Gray mold | |
| Bentzon-Tilia et al. | Biotechnological applications of the Roseobacter clade | |
| WO2016027279A1 (en) | Novel bacterium of bacillus genus and uses thereof | |
| Shayesteh et al. | In vitro anti-biofilm activity of bacteriocin from a marine Bacillus sp. strain Sh10 against Proteus mirabilis | |
| MA29237B1 (fr) | Antibiotique 107891, ses facteurs a1 et a2, ses sels pharmaceutiquement acceptables, compositions en contenant, et leurs utilisations | |
| TW200510541A (en) | Antibiotic 107891, its factors A1 and A2, pharmaceutically acceptable salts and compositions, and use thereof | |
| Hein-Kristensen et al. | Selectivity in the potentiation of antibacterial activity of α-peptide/β-peptoid peptidomimetics and antimicrobial peptides by human blood plasma | |
| Zhong et al. | The role of single and mixed biofilms in Clostridioides difficile infection and strategies for prevention and inhibition | |
| E. Gustafson, Sean D. Cox, Yoon C. Liew, S. Grant Wyllie, John R. Warmington | The bacterial multiple antibiotic resistant (Mar) phenotype leads to increased tolerance to tea tree oil |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A85 | Still pending on 85-01-01 | ||
| BA | A request for search or an international-type search has been filed | ||
| BB | A search report has been drawn up | ||
| BC | A request for examination has been filed | ||
| BV | The patent application has lapsed |